Crescent Biopharma (CBIO) Common Equity (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Common Equity of $163.3 million for Q2 2026, up 17.24% year-over-year from $139.3 million in Q2 2025, and down 11.2% quarter-over-quarter from $183.8 million in Q1 2026.
Crescent Biopharma (CBIO) Common Equity (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Common Equity for 14 consecutive years, with $163.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity rose 17.24% year-over-year to $163.3 million; the TTM figure through Jun 2026 stood at $163.3 million (up 17.24% YoY), while the FY2025 annual figure was $203.0 million, up 1411.53% from the prior year.
- Common Equity retreated to $163.3 million in Q2 2026 per CBIO's latest filing, from $183.8 million in the prior quarter.
- Across five years, Common Equity topped out at $203.0 million in Q4 2025 and bottomed at -$30.2 million in Q1 2025.
- Historically, Common Equity has averaged $68.0 million across 5 years, with a median of $51.5 million in 2022.
- On a YoY basis, Common Equity climbed as much as 9058.6% in 2025 and fell as far as 204.32% in 2025.
- Crescent Biopharma's Common Equity stood at $42.9 million in 2022, then retreated by 10.52% to $38.4 million in 2023, then sank by 140.29% to -$15.5 million in 2024, then soared by 1411.53% to $203.0 million in 2025, then decreased by 19.58% to $163.3 million in 2026.
- Business Quant data shows CBIO's Common Equity at $163.3 million in Q2 2026, $183.8 million in Q1 2026, and $203.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Crescent Biopharma | 1.05 Bn | 875.92 Mn | - | 163.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 163.26 Mn |
| Mar 31, 2026 | 183.85 Mn |
| Dec 31, 2025 | 203.01 Mn |
| Sep 30, 2025 | 116.64 Mn |
| Jun 30, 2025 | 139.25 Mn |
| Mar 31, 2025 | -30.16 Mn |
| Dec 31, 2024 | -15.48 Mn |
| Sep 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | 20.06 Mn |
| Mar 31, 2024 | 28.91 Mn |
| Dec 31, 2023 | 38.41 Mn |
| Sep 30, 2023 | 46.55 Mn |
| Jun 30, 2023 | 54.80 Mn |
| Mar 31, 2023 | 62.18 Mn |
| Dec 31, 2022 | 42.93 Mn |
| Sep 30, 2022 | 48.12 Mn |
| Jun 30, 2022 | 55.73 Mn |
| Mar 31, 2022 | 68.03 Mn |
| Dec 31, 2021 | 81.60 Mn |
| Sep 30, 2021 | 96.57 Mn |